FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588472023> ?p ?o ?g. }

• W2588472023 endingPage "vi130" @default.
• W2588472023 startingPage "vi130" @default.
• W2588472023 abstract "Advanced biliary tract carcinomas (ABC) are fatal malignancies with limited effective therapeutic alternatives for advanced disease. Following first line treatment, clinical trials using experimental novel therapeutic agents may be considered for selected patients. This study describes the experience of ABC patients treated in a specialized phase 1 unit. Patient characteristics, tumour features, treatment details and clinical outcomes of ABC patients treated at the Drug Development Unit, Royal Marsden Hospital, between 2002 and 2016, were captured and analysed from case and trial records. 123 ABC patients were included in the study, of which 48 patients participated in 41 different phase 1 trials. Patients had a median of 2 previous lines of systemic chemotherapy (range 1 – 6). 8 (17%) entered a second phase 1 study upon progression on the first study. 15 (31%) had molecular characterization of tumours using a targeted panel, yielding 7 potentially actionable mutations including BRCA (2), PIK3CA (2), FGFR, AKT and PTEN loss. However, due to logistical reasons, none of them received treatment on a trial matched to these mutations. Of the 39 evaluable patients, there was one exceptional responder who had a partial response (PR) that continues to be maintained at 1.5 years on a PARP inhibitor study. 18 patients (46%) achieved stable disease (SD) as their best response, and this was sustained for more than 6 cycles (18 weeks) in 4 patients (8%). Median progression free survival was 6.1 weeks (95 %CI 3.3 – 9.3) and median overall survival was 22.0 weeks (95 %CI 18.8 – 25.2). Treatment was generally well tolerated with grade 3 or 4 adverse events only observed in 8 patients (17 %) of which 6 were drug related and led to trial discontinuation in 1 (3%), with no toxicity related deaths. Experimental phase 1 clinical trials are a reasonable and safe alternative for selected patients with ABC. Several actionable mutations were identified by our targeted panel; however due to logistical reasons none were enrolled onto matched trials. Future work requires more comprehensive molecular profiling to understand the biology underlying the exceptional response, to identify new treatment options, and to match patients in real-time to targeted therapies." @default.
• W2588472023 created "2017-02-24" @default.
• W2588472023 creator A5014804968 @default.
• W2588472023 creator A5032401979 @default.
• W2588472023 creator A5032751530 @default.
• W2588472023 creator A5053619368 @default.
• W2588472023 creator A5063018089 @default.
• W2588472023 creator A5064237640 @default.
• W2588472023 creator A5068368047 @default.
• W2588472023 creator A5072378199 @default.
• W2588472023 creator A5074441562 @default.
• W2588472023 creator A5091263091 @default.
• W2588472023 date "2016-10-01" @default.
• W2588472023 modified "2023-10-17" @default.
• W2588472023 title "Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit" @default.
• W2588472023 doi "https://doi.org/10.1093/annonc/mdw368.47" @default.
• W2588472023 hasPublicationYear "2016" @default.
• W2588472023 type Work @default.
• W2588472023 sameAs 2588472023 @default.
• W2588472023 citedByCount "0" @default.
• W2588472023 crossrefType "journal-article" @default.
• W2588472023 hasAuthorship W2588472023A5014804968 @default.
• W2588472023 hasAuthorship W2588472023A5032401979 @default.
• W2588472023 hasAuthorship W2588472023A5032751530 @default.
• W2588472023 hasAuthorship W2588472023A5053619368 @default.
• W2588472023 hasAuthorship W2588472023A5063018089 @default.
• W2588472023 hasAuthorship W2588472023A5064237640 @default.
• W2588472023 hasAuthorship W2588472023A5068368047 @default.
• W2588472023 hasAuthorship W2588472023A5072378199 @default.
• W2588472023 hasAuthorship W2588472023A5074441562 @default.
• W2588472023 hasAuthorship W2588472023A5091263091 @default.
• W2588472023 hasBestOaLocation W25884720231 @default.
• W2588472023 hasConcept C121608353 @default.
• W2588472023 hasConcept C126322002 @default.
• W2588472023 hasConcept C141071460 @default.
• W2588472023 hasConcept C143998085 @default.
• W2588472023 hasConcept C2776694085 @default.
• W2588472023 hasConcept C2780258809 @default.
• W2588472023 hasConcept C3017919176 @default.
• W2588472023 hasConcept C31760486 @default.
• W2588472023 hasConcept C535046627 @default.
• W2588472023 hasConcept C71924100 @default.
• W2588472023 hasConceptScore W2588472023C121608353 @default.
• W2588472023 hasConceptScore W2588472023C126322002 @default.
• W2588472023 hasConceptScore W2588472023C141071460 @default.
• W2588472023 hasConceptScore W2588472023C143998085 @default.
• W2588472023 hasConceptScore W2588472023C2776694085 @default.
• W2588472023 hasConceptScore W2588472023C2780258809 @default.
• W2588472023 hasConceptScore W2588472023C3017919176 @default.
• W2588472023 hasConceptScore W2588472023C31760486 @default.
• W2588472023 hasConceptScore W2588472023C535046627 @default.
• W2588472023 hasConceptScore W2588472023C71924100 @default.
• W2588472023 hasLocation W25884720231 @default.
• W2588472023 hasOpenAccess W2588472023 @default.
• W2588472023 hasPrimaryLocation W25884720231 @default.
• W2588472023 hasRelatedWork W1994207653 @default.
• W2588472023 hasRelatedWork W2024219304 @default.
• W2588472023 hasRelatedWork W2043917781 @default.
• W2588472023 hasRelatedWork W2080820783 @default.
• W2588472023 hasRelatedWork W2100029565 @default.
• W2588472023 hasRelatedWork W2113566724 @default.
• W2588472023 hasRelatedWork W2315587357 @default.
• W2588472023 hasRelatedWork W3032349186 @default.
• W2588472023 hasRelatedWork W3142786019 @default.
• W2588472023 hasRelatedWork W4249900186 @default.
• W2588472023 hasVolume "27" @default.
• W2588472023 isParatext "false" @default.
• W2588472023 isRetracted "false" @default.
• W2588472023 magId "2588472023" @default.
• W2588472023 workType "article" @default.